Document Type : Original Research Article
Authors
1 Al-Elweyia Maternity Teaching Hospital, Baghdad, Iraq.
2 Professor / Consultant OBG, Medical College Mustansiriyah University, Baghdad- Iraq.
3 F.I.C.M.S, E.B.U
Abstract
Background: gonadotropin-releasing hormone acts on the anterior pituitary and promotes the release of both follicle-stimulating hormone (FSH) and luteinizing hormone (LH), both of great importance in the ovarian cycle.
Method: A prospective cross sectional study conducted at the High Institute for Infertility Diagnosis and Assisted Reproductive Technologies / Al-Nahrain University and Kamal Al-Sameraie hospital for infertility& in vitro fertilization, Baghdad-Iraq during the period from April 2022 to April 2023, women received rFSH in a single daily dose of (150-300 IU) for ovarian stimulation. Women in group B and C received ovarian stimulation antagonist while those in the group A were not
Results: Both clinical and ongoing pregnancy rates were measured for each Group. Positive hCG test was found in 27 (79.4%) in Group A while it was positive in 19 (55.9%) in Group B with significant difference (P=0.03), clinical pregnancy was 25 (73.5%) in Group A while it was positive in 17 (50.0%) in Group B with significant difference (P=0.04), and ongoing pregnancy was found in 24 (70.6%) in Group A while it was positive in 15 (44.1%) in Group B with significant difference (P=0.01).
Conclusion: women with LH <4 IU presented with significant increase in pregnancy rate than those with ≥4 IU, and do not need for GnRH antagonist addition as co treatment.
Keywords
- Infertility
- Luteinizing Hormone
- Mineralocorticoid Receptor Antagonists
- pregnancy rate
- Gonadotropin-Releasing Hormone
Main Subjects
)